Drug intelligence / Profile preview

GHB-004

Development stage: Preclinical
Lead developer: Gatehouse Bio
Modality: RNA Therapeutics → Nucleic Acid Therapeutics

Overview

GHB-004 is a preclinical-stage therapeutic candidate being developed by Gatehouse Bio for the treatment of non-alcoholic steatohepatitis (NASH). The drug is part of Gatehouse Bio's pipeline of small RNA (sRNA) therapeutics, which are identified and developed using the company's proprietary AI-driven platform. This platform analyzes sRNA signatures to discover novel disease drivers and therapeutic targets. As of early 2024, GHB-004 remains in the preclinical development phase, with specific molecular targets and detailed mechanisms of action not yet publicly disclosed.

Beyond the preview

Go deeper on GHB-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GHB-004.

Explore the full profile